Renaissance Technologies LLC Raises Stake in Boston Scientific Corporation $BSX

Posted by George Bondi on Jul 25th, 2026

Boston Scientific logo Renaissance Technologies LLC grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 32.3% during the 1st quarter, HoldingsChannel reports. The fund owned 3,152,005 shares of the medical equipment provider’s stock after acquiring an additional 769,300 shares during the quarter. Renaissance Technologies LLC’s holdings in Boston Scientific were worth $197,788,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BSX. Norges Bank bought a new position in shares of Boston Scientific during the 4th quarter valued at $2,199,395,000. Assenagon Asset Management S.A. lifted its stake in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after purchasing an additional 5,751,760 shares during the last quarter. Maverick Capital Ltd. purchased a new stake in Boston Scientific during the fourth quarter valued at about $280,735,000. Arrowstreet Capital Limited Partnership boosted its position in Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after buying an additional 2,856,040 shares during the period. Finally, Farallon Capital Management LLC grew its stake in shares of Boston Scientific by 56.7% during the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock valued at $709,362,000 after buying an additional 2,693,007 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Boston Scientific stock opened at $44.26 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a market cap of $65.78 billion, a P/E ratio of 18.52, a P/E/G ratio of 0.84 and a beta of 0.58. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The firm has a 50-day moving average of $47.21 and a 200-day moving average of $64.06.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.35 EPS for the current year.

Boston Scientific announced that its board has approved a stock buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Bank of America decreased their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research report on Thursday, May 28th. Royal Bank Of Canada dropped their price objective on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Mizuho cut their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.84.

Read Our Latest Stock Report on BSX

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.